- Rockwell Medical (NSD:RMTI) announced that its South Korean partner Jeil Pharmaceutical has received regulatory approval for Triferic Injection
- Rockwell Medical has an exclusive license agreement with Jeil for the rights to commercialize Triferic in South Korea
- Rockwell Medical has received an upfront fee and will be eligible for milestone payments and royalties on net sales
- Product sales are anticipated to begin in mid 2022
- Dr. Russell Ellison, President and CEO of Rockwell Medical sat down with Dave Jackson to discuss the approval
- Rockwell Medical is a commercial-stage biopharmaceutical company
- Rockwell Medical Inc. (NSD:RMTI) is up 22.55 per cent, trading at US$0.49 per share at 2:15 pm EST
Rockwell Medical (NSD: RMTI) announced that its South Korean partner Jeil Pharmaceutical has received regulatory approval for Triferic Injection.
Rockwell Medical has an exclusive license agreement with Jeil for the rights to commercialize Triferic in South Korea. Under the terms of the license agreement, Jeil is the exclusive development and commercialization partner for Triferic in South Korea.
Rockwell Medical will supply the product to Jeil. Rockwell Medical has received an upfront fee and will be eligible for milestone payments and royalties on net sales.
Product sales are anticipated to begin in June/July of 2022.
Dr. Russell Ellison, President and CEO of Rockwell Medical sat down with Dave Jackson to discuss the approval.
“The approval by MFDS is an important milestone for Rockwell Medical, but more importantly, for the more than 82,000 patients in South Korea undergoing hemodialysis. With its considerable development and commercialization capabilities and local market expertise, we believe Jeil is well positioned to ensure that hemodialysis patients have access to our innovative therapeutic across South Korea. Today’s announcement marks another meaningful advancement for Triferic, as we build our global footprint and increase the long-term value of Triferic.”
Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron deficiency treatment platform, Ferric Pyrophosphate Citrate (FPC).
Rockwell Medical Inc. (NSD:RMTI) is up 22.55 per cent, trading at US$0.49 per share at 2:15 pm EST.
